My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

MannKind Corporation - Common Stock (NQ:MNKD)

5.940 +0.130 (+2.24%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 12, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about MannKind Corporation - Common Stock

< Previous 1 2 3 4 5 Next >

MannKind Stock Nears Breakout As FDA Reviews First New Insulin For Kids In A Century ↗

November 06, 2025

Via Stocktwits

MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters ↗

November 05, 2025

Via Stocktwits

MannKind Corp (NASDAQ:MNKD) Reports Q3 2025 Earnings Beat, Shares Rise ↗

November 05, 2025

MannKind (MNKD) Q3 2025 results beat revenue and EPS estimates. The biopharma's shares rose on strong performance and strategic updates, including the scPharmaceuticals acquisition.

Via Chartmill

Topics Earnings

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

September 09, 2025

Via Benzinga

MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results ↗

September 02, 2025

Via Stocktwits

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together ↗

August 27, 2025

Via Stocktwits

There are notable gap-ups and gap-downs in today's session. ↗

September 02, 2025

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Tuesday's pre-market session: top gainers and losers ↗

September 02, 2025

As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 02, 2025

Via Benzinga

MannKind Announces $500M Financing Agreement With Blackstone After Q2 Revenue Miss: Retail Believes Stock Is ‘Ridiculously Undervalued’ ↗

August 06, 2025

Via Stocktwits

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

A Look Ahead: MannKind's Earnings Forecast ↗

August 05, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

MannKind's Earnings Outlook ↗

May 07, 2025

Via Benzinga

MannKind’s $360M scPharma Deal Splits Analysts — Retail Traders Call It ‘Bizarro Territory’ But Stay Bullish ↗

August 25, 2025

The deal hands MannKind access to scPharma’s Furoscix heart and kidney therapy, a product with a U.S. market potential estimated at over $10 billion.

Via Stocktwits

MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal ↗

August 25, 2025

MannKind will acquire scPharmaceuticals in a $360 million deal, adding Furoscix and expanding into cardiometabolic care with a $10 billion U.S. market opportunity.

Via Benzinga

MannKind Corporation to Acquire scPharmaceuticals: More Details Inside ↗

August 25, 2025

The transaction is expected to close in the fourth quarter of 2025, subject to necessary approvals.

Via Stocktwits

MannKind (MNKD) Q2 Revenue Rises 6% ↗

August 06, 2025

Via The Motley Fool

Topics Intellectual Property World Trade

MannKind Corp (NASDAQ:MNKD) Q2 2025 Earnings Miss Estimates, Shares Drop 3.8% in Pre-Market ↗

August 06, 2025

MannKind Corp (MNKD) missed Q2 2025 revenue and EPS estimates, causing a 3.8% pre-market drop. Despite the miss, strategic moves like Blackstone's $500M financing and product pipeline progress offer...

Via Chartmill

Topics Earnings

Earnings Scheduled For February 26, 2025 ↗

February 26, 2025

Via Benzinga

Top 3 Health Care Stocks That May Rocket Higher This Quarter ↗

June 11, 2025

Via Benzinga

This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

April 10, 2025

Via Benzinga

MannKind Stock Surges After-Hours On Q4 Revenue Beat, Debt Reduction As Retail Investors Celebrate ‘Amazing Comeback’ ↗

February 27, 2025

The company significantly reduced its debt principal by $236 million, leaving just $36 million in remaining convertible debt, and ended 2024 with $203 million in cash, cash equivalents, and...

Via Stocktwits

MannKind (MNKD) Q4 2024 Earnings Call Transcript ↗

February 27, 2025

MNKD earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

December 20, 2024

Via Benzinga

Topics Stocks

MannKind Shares Are falling Today: What's Going On? ↗

December 16, 2024

MannKind Corporation (NASDAQ: MNKD) are trading lower Monday. The company released its six-month results from its Phase 3 INHALE-1 pediatric diabetes trial. Here's what you need to know.

Via Benzinga

MannKind (MNKD) Q3 2024 Earnings Call Transcript ↗

November 07, 2024

MNKD earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 23, 2024

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.